Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HJ-004-02
- Development stage
- Phase 1
- Lead developer
- Jing Medicine Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HJ-004-02 is an investigational, fourth-generation small molecule tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR). Developed by Tongji University, specifically through the Shanghai Pulmonary Hospital, it is designed to overcome resistance mutations, such as the C797S mutation, which frequently develop in patients with non-small cell lung cancer (NSCLC) following treatment with third-generation EGFR inhibitors like osimertinib. The drug is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced non-squamous NSCLC harboring EGFR mutations. HJ-004-02 is administered orally as a tablet.
02
Targets
Beyond the preview
Go deeper on HJ-004-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HJ-004-02.